Page last updated: 2024-12-07

glycerophosphoethanolamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

glycerol 3-phosphoethanolamine: a membrane lipid degradation product [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123874
CHEBI ID52330
SCHEMBL ID692470
MeSH IDM0043049

Synonyms (36)

Synonym
1190-00-7
glycerophosphoethanolamine
glycerophosphorylethanolamine
CHEBI:52330
sn-glycerol-3-phosphoethanolamine
glycerophosphatidylethanolamine
2-aminoethyl 2,3-dihydroxypropyl hydrogen phosphate
2-aminoethyl (2,3-dihydroxypropyl) hydrogen phosphate
FT-0688264
240i539pwq ,
phosphoric acid, mono(2-aminoethyl) mono(2,3-dihydroxypropyl) ester
unii-240i539pwq
SCHEMBL692470
l-a-glycerophosphorylethanolamine*from e coli
glyceryl-3-phosphorylethanolamine
glycerylphosphoethanolamine
.alpha.-glycerophosphorylethanolamine, (rs)-
.alpha.-glycerophosphorylethanolamine
glycerophosphoethanolamine [who-dd]
.alpha.-glycerophosphorylethanolamine, (+/-)-
glycerol 3-phosphoethanolamine
FT-0699527
gpea
a-glycerophosphorylethanolamine
alpha-glycerophosphorylethanolamine
2-aminoethyl ester 1-glycerophosphoric acid
glycerol 3-phosphorylethanolamine
2-aminoethyl (2,3-dihydroxypropyl)hydrogen phosphate
Q27123382
(+/-)-alpha-glycerophosphorylethanolamine
(2-aminoethoxy)(2,3-dihydroxypropoxy)phosphinic acid
A936512
glycerophosphoryethanolamine
2-aminoethyl(2,3-dihydroxypropyl)hydrogenphosphate
DTXSID20862586
PD041309

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" To overcome this metabolic compromise, we have designed an orally bioavailable DHA-containing ether lipid precursor of plasmalogens."( Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease.
Ehrmantraut, G; Goodenowe, DB; Khan, MA; Lane, N; Smith, T; Wood, PL, 2011
)
0.37
"Our data demonstrate that PPI-1011, an ether lipid precursor of plasmalogens is orally bioavailable in the rabbit, augmenting the circulating levels of unesterified DHA and DHA-containing PlsEtn and PtdEtn."( Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease.
Ehrmantraut, G; Goodenowe, DB; Khan, MA; Lane, N; Smith, T; Wood, PL, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
"Rabbits were dosed orally with PPI-1011 in hard gelatin capsules for time-course and dose response studies."( Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease.
Ehrmantraut, G; Goodenowe, DB; Khan, MA; Lane, N; Smith, T; Wood, PL, 2011
)
0.37
" Isotope and repeated dosing (2 weeks) experiments also demonstrated that plasmalogens and/or plasmalogen precursors derived from PPI-1011 are able to cross both the blood-retinal and blood-brain barriers."( Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease.
Ehrmantraut, G; Goodenowe, DB; Khan, MA; Lane, N; Smith, T; Wood, PL, 2011
)
0.37
" Repeated oral dosing for 2 weeks with PPI-1011 resulted in dose-dependent increases in circulating DHA and DHA-containing plasmalogens."( Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease.
Ehrmantraut, G; Goodenowe, DB; Khan, MA; Lane, N; Smith, T; Wood, PL, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
phosphoethanolamine
sn-glycerol 3-phosphates
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Biochemical pathways: part I0466

Research

Studies (140)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (22.14)18.7374
1990's39 (27.86)18.2507
2000's29 (20.71)29.6817
2010's31 (22.14)24.3611
2020's10 (7.14)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.25

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.25 (24.57)
Research Supply Index5.01 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index29.35 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.25)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.36%)5.53%
Reviews3 (2.04%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other142 (96.60%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]